Delving into the Latest Updates on T10-F10 with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

CMV三联疫苗(City of Hope), Triplex vaccine candidate(City of Hope)

Target

CMV IE2 x CMV pp65

Action

inhibitors

Mechanism

CMV IE2 inhibitors(major immediate early region inhibitors), CMV pp65 inhibitors(Cytomegalovirus pp65 Antigen inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Cytomegalovirus Infections

Inactive Indication-

Originator Organization

City of Hope National Medical Center

Active Organization

City of Hope National Medical Center

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

AbstractHuman cytomegalovirus (CMV) is the most common infectious cause of complications post-transplantation, while a CMV vaccine for transplant recipients has yet to be licensed. Triplex, a multiantigen Modified Vaccinia Ankara (MVA)-vectored CMV vaccine candidate based on the immunodominant antigens phosphoprotein 65 (pp65) and immediate-early 1 and 2 (IE1/2), is in an advanced stage of clinical development. However, its limited genetic and expression stability restricts its potential for large-scale production. Using a recently developed fully synthetic MVA (sMVA) platform, we developed a new generation Triplex vaccine candidate, T10-F10, with different sequence modifications for enhanced vaccine stability. T10-F10 demonstrated genetic and expression stability during extensive virus passaging. In addition, we show that T10-F10 confers comparable immunogenicity to the original Triplex vaccine to elicit antigen-specific T cell responses in HLA-transgenic mice. These results demonstrate improvements in translational vaccine properties of an sMVA-based CMV vaccine candidate designed as a therapeutic treatment for transplant recipients.

100 Deals associated with T10-F10

Login to view more data